146 related articles for article (PubMed ID: 38188143)
21. SHMT2 Induces Stemness and Progression of Head and Neck Cancer.
Jin Y; Jung SN; Lim MA; Oh C; Piao Y; Kim HJ; Nguyena Q; Kang YE; Chang JW; Won HR; Koo BS
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077112
[TBL] [Abstract][Full Text] [Related]
22. Cytoplasmic SHMT2 drives the progression and metastasis of colorectal cancer by inhibiting β-catenin degradation.
Liu C; Wang L; Liu X; Tan Y; Tao L; Xiao Y; Deng P; Wang H; Deng Q; Lin Y; Jie H; Zhang H; Zhang J; Peng Y; Zhang H; Zhou Z; Sun Q; Cen X; Zhao Y
Theranostics; 2021; 11(6):2966-2986. PubMed ID: 33456583
[No Abstract] [Full Text] [Related]
23. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S; Bayerlová M; Vetter M; Wachter A; Mitra D; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Thomssen C; Korf U; Beissbarth T; Wiemann S; Kantelhardt EJ
Breast Cancer Res; 2017 Oct; 19(1):112. PubMed ID: 29020998
[TBL] [Abstract][Full Text] [Related]
24. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
[TBL] [Abstract][Full Text] [Related]
25. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA CRNDE is a novel tumor promoter by modulating PI3K/AKT signal pathways in human gastric cancer.
Du DX; Lian DB; Amin BH; Yan W
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5392-5398. PubMed ID: 29243780
[TBL] [Abstract][Full Text] [Related]
27. Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.
Clark RA; Qiao J; Jacobson JC; Chung DH
Oncotarget; 2022; 13():32-45. PubMed ID: 35018218
[TBL] [Abstract][Full Text] [Related]
28. Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation.
Liao Y; Wang F; Zhang Y; Cai H; Song F; Hou J
Cancer Cell Int; 2021 Apr; 21(1):220. PubMed ID: 33863325
[TBL] [Abstract][Full Text] [Related]
29. RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer.
Cheng Y; Yang B; Xi Y; Chen X
Tumour Biol; 2016 Nov; 37(11):14969-14978. PubMed ID: 27651161
[TBL] [Abstract][Full Text] [Related]
30. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis.
Wei Z; Song J; Wang G; Cui X; Zheng J; Tang Y; Chen X; Li J; Cui L; Liu CY; Yu W
Nat Commun; 2018 Oct; 9(1):4468. PubMed ID: 30367038
[TBL] [Abstract][Full Text] [Related]
31. Expression and Clinical Significance of
Liang T; Da MX
Comb Chem High Throughput Screen; 2023; 26(12):2194-2200. PubMed ID: 36757044
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer.
Peng XC; Zeng Z; Huang YN; Deng YC; Fu GH
Cancer Med; 2018 Jun; 7(6):2592-2600. PubMed ID: 29665316
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of mitochondrial serine hydroxyl-methyltransferase 2 is associated with poor prognosis and promotes cell proliferation and invasion in gliomas.
Wu M; Wanggou S; Li X; Liu Q; Xie Y
Onco Targets Ther; 2017; 10():3781-3788. PubMed ID: 28794642
[TBL] [Abstract][Full Text] [Related]
34. High expression of the circadian clock gene NPAS2 is associated with progression and poor prognosis of gastric cancer: A single-center study.
Cao XM; Kang WD; Xia TH; Yuan SB; Guo CA; Wang WJ; Liu HB
World J Gastroenterol; 2023 Jun; 29(23):3645-3657. PubMed ID: 37398880
[TBL] [Abstract][Full Text] [Related]
35. GPR116 overexpression correlates with poor prognosis in gastric cancer.
Zheng T; Sun M; Liu L; Lan Y; Wang L; Lin F
Medicine (Baltimore); 2021 Dec; 100(48):e28059. PubMed ID: 35049225
[TBL] [Abstract][Full Text] [Related]
36. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
37. LUM as a novel prognostic marker and its correlation with immune infiltration in gastric cancer: a study based on immunohistochemical analysis and bioinformatics.
Xu W; Chen S; Jiang Q; He J; Zhang F; Wang Z; Ruan C; Shi B
BMC Gastroenterol; 2023 Dec; 23(1):455. PubMed ID: 38129820
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools.
Liu J; Liu Z; Zhang X; Gong T; Yao D
BMC Cancer; 2019 Mar; 19(1):227. PubMed ID: 30866865
[TBL] [Abstract][Full Text] [Related]
39. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.
Deng H; Li T; Wei F; Han W; Xu X; Zhang Y
Pathol Oncol Res; 2023; 29():1610893. PubMed ID: 36741965
[No Abstract] [Full Text] [Related]
40.
Situ Y; Zhang J; Liao W; Liang Q; Lu L; Xu Q; Chen J; Lu X; Cui Y; Shao Z; Deng L
Front Biosci (Landmark Ed); 2023 Sep; 28(9):196. PubMed ID: 37796681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
